Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Risk of endometrial cancer and estrogen replacement therapy history by CYP17 genotype.

Cancer research - 1 Feb 2001

McKean-Cowdin R, Feigelson H S, Pike M C, Coetzee G A, Kolonel L N, Henderson B E

Abstract excerpt

Common variants among genes coding for enzymes in sex steroid biosynthetic pathways may influence the risk of endometrial cancer. We examined the association between endometrial cancer risk and estrogen replacement therapy (ERT) by CYP17 genotype using 51 incident cases and 391 randomly selected controls from a multiethnic cohort in Hawaii and Los Angeles, California. The relative risk of endometrial cancer was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Case-Control Studies
Share to Endometrial Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Estrogen Replacement Therapy

Share to Genetic Predisposition to Disease

Share to Genotype

Share to Risk Factors

Share to Steroid 17-alpha-Hydroxylase

Source

Identifiers

PMID: 11221867

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Risk of endometrial cancer and estrogen replacement therapy history by CYP17 genotype.PMID 11221867Read ↗

Estrogen sulfation genes, hormone replacement therapy, and endometrial cancer risk.Semantic proximity Read ↗

Variations in sex hormone metabolism genes, postmenopausal hormone therapy and risk of endometrial cancer.Semantic proximity Read ↗

A polymorphism in CYP17 and endometrial cancer risk.Semantic proximity Read ↗

Estrogen-biosynthesis gene CYP17 and its interactions with reproductive, hormonal and lifestyle factors in breast cancer risk: results from the Long Island Breast Cancer Study Project.Semantic proximity Read ↗

Cytochrome P450c17alpha gene (CYP17) polymorphism predicts use of hormone replacement therapy.Semantic proximity Read ↗

Variants in estrogen biosynthesis genes, sex steroid hormone levels, and endometrial cancer: a HuGE review.Semantic proximity Read ↗

CYP1A1, SULT1A1, and SULT1E1 polymorphisms are risk factors for endometrial cancer susceptibility.Semantic proximity Read ↗

Polymorphisms in genes hydroxysteroid-dehydrogenase-17b type 2 and type 4 and endometrial cancer risk.Semantic proximity Read ↗

Postmenopausal estrogen monotherapy-associated breast cancer risk is modified by CYP17A1_-34_T>C polymorphism.Semantic proximity Read ↗

Pharmacogenetic modulation of combined hormone replacement therapy by progesterone-metabolism genotypes in postmenopausal breast cancer risk.Semantic proximity Read ↗

Genetic factors in catechol estrogen metabolism in relation to the risk of endometrial cancer.Semantic proximity Read ↗

Genetic variation of the CYP17 and susceptibility to endometrial cancer: a meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.